Background: Several studies have suggested an association between aspirin (acetylsalicylate) use and improved cancer survival. The mechanism behind the beneficial effect is not completely clarified. One of the hypothesis is that circulating tumour cells (CTC's) are guarded from the immune system by thrombocytes. When the aggregation of thrombocytes is inhibited, the protection of the CTC's vanishes and the immune system will be able to clear the CTC’s. Aspirin is a thrombocyte aggregation inhibitor (TAI) and could in this way reduce the mortality in patients with colorectal cancer.

Advertisements on this site do not constitute a guarantee or endorsement by the journal, Association, or publisher of the quality or value of such product or of the claims made for it by its manufacturer.